http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0946877-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bbadc41aa91592752369d88100f96411 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 |
filingDate | 1997-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf0351f97719ad4be23bd9a2342f28db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9286b015eb9a10b78d084680c7d306a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_677871e44066f7e80cd74b396f4ceefd |
publicationDate | 1999-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-0946877-A1 |
titleOfInvention | P-selectin assays and methods of use thereof |
abstract | The present invention relates to a method of assessing the effect of 'anti-platelet' agents, which affect the activation state of platelets, by monitoring levels of membrane bound and/or soluble P-selectin in a sample from an individual. In one embodiment, levels of P-selectin are monitored in a sample containing platelets (e.g., a blood sample, platelet rich plasma (PRP)) using an assay for membrane bound P-selectin. In another embodiment, levels of P-selectin are measured in a sample from which platelets have been removed (e.g., platelet poor plasma (PPP), serum), using an assay for soluble P-selectin. Another aspect of the invention includes measuring both membrane bound and soluble P-selectin to monitor platelet activation for patients who are receiving anti-platelet therapy. The method is useful for monitoring the effect of anti-platelet therapy on platelet activation state as reflected in membrane bound and/or soluble P-selectin levels. Anti-platelet therapy can be adjusted accordingly to maintain a desired level of platelet activation. In another aspect, the invention relates to a method of assessing the effect of a vascular intervention, and of coronary artery interventions in particular, on platelet activation state comprising determining the level of soluble P-selectin in a sample. Anti-platelet therapy can be initiated or adjusted in order to achieve a basal activation state, or other desired platelet activation state. |
priorityDate | 1996-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 422.